Literature DB >> 24534777

The treatment of mild cervical spondylotic myelopathy with increased signal intensity on T2-weighted magnetic resonance imaging.

F N Li1, Z H Li2, X Huang3, S Z Yu4, F Zhang3, Z Chen3, H X Shen3, B Cai3, T S Hou3.   

Abstract

STUDY
DESIGN: A retrospective comparative study.
OBJECTIVES: To compare clinical outcomes of surgery or non-operated treatment for mild cervical spondylotic myelopathy (CSM) patients with intramedullary increased signal intensity (ISI) on T2-weighted imaging (T2WI) of magnetic resonance imaging (MRI), related factors that may affect prognosis were explored.
METHODS: Data from 91 patients treated from July 2008 to June 2011 were retrospectively analyzed. The Japanese Orthopedic Association (JOA) recovery ratio was used to compare outcomes of surgery and non-operated treatment. Correlation and multiple linear regression analyses were performed between JOA recovery ratio and age, disease course, segmental lordosis, total range of motion (ROM), segmental ROM, local slip, extent of spinal cord compression or ISI type.
RESULTS: Patients were divided into two groups by therapy methods: Group A (n=53, 33 males, age 36-68 years) underwent anterior cervical decompression and fusion surgery, average follow-up 30.68±8.19 months; Group B (n=38, 14 males, age 28-76 years) received non-operated treatment, average follow-up 34.08±9.05 months. There were no significant differences in clinical outcomes between the two groups. There were significant correlations between JOA recovery ratio and clinical course (P<0.01) or segmental lordosis (P<0.01). Patients with shorter disease course and larger segmental lordosis have better clinical outcomes as shown by multiple linear regression analysis.
CONCLUSION: For mild CSM patients with ISI on T2WI-MRI, there are no significant differences in clinical outcome between surgery and non-operated treatment during the short-term follow-up. Patients with shorter disease course and larger segmental lordosis have better clinical outcomes than those with longer course and segmental kyphosis.

Entities:  

Mesh:

Year:  2014        PMID: 24534777     DOI: 10.1038/sc.2014.11

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  4 in total

Review 1.  Change in Function, Pain, and Quality of Life Following Structured Nonoperative Treatment in Patients With Degenerative Cervical Myelopathy: A Systematic Review.

Authors:  Lindsay A Tetreault; John Rhee; Heidi Prather; Brian K Kwon; Jefferson R Wilson; Allan R Martin; Ian B Andersson; Anna H Dembek; Krystle T Pagarigan; Joseph R Dettori; Michael G Fehlings
Journal:  Global Spine J       Date:  2017-09-05

Review 2.  Nonoperative Versus Operative Management for the Treatment Degenerative Cervical Myelopathy: An Updated Systematic Review.

Authors:  John Rhee; Lindsay A Tetreault; Jens R Chapman; Jefferson R Wilson; Justin S Smith; Allan R Martin; Joseph R Dettori; Michael G Fehlings
Journal:  Global Spine J       Date:  2017-09-05

3.  Mir21 modulates inflammation and sensorimotor deficits in cervical myelopathy: data from humans and animal models.

Authors:  Alex M Laliberte; Spyridon K Karadimas; Pia M Vidal; Kajana Satkunendrarajah; Michael G Fehlings
Journal:  Brain Commun       Date:  2021-01-21

4.  A Clinical Practice Guideline for the Management of Patients With Degenerative Cervical Myelopathy: Recommendations for Patients With Mild, Moderate, and Severe Disease and Nonmyelopathic Patients With Evidence of Cord Compression.

Authors:  Michael G Fehlings; Lindsay A Tetreault; K Daniel Riew; James W Middleton; Bizhan Aarabi; Paul M Arnold; Darrel S Brodke; Anthony S Burns; Simon Carette; Robert Chen; Kazuhiro Chiba; Joseph R Dettori; Julio C Furlan; James S Harrop; Langston T Holly; Sukhvinder Kalsi-Ryan; Mark Kotter; Brian K Kwon; Allan R Martin; James Milligan; Hiroaki Nakashima; Narihito Nagoshi; John Rhee; Anoushka Singh; Andrea C Skelly; Sumeet Sodhi; Jefferson R Wilson; Albert Yee; Jeffrey C Wang
Journal:  Global Spine J       Date:  2017-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.